Overview

• Researchers from Centro Médico Santa María de la Salud, Hospital Universitario Austral and Instituto BIOMED (UCA-CONICET) enrolled 130 adults with hypertension and dyslipidemia in a double-blind, placebo-controlled trial.
• Participants received two 1 g capsules daily of a high-purity EPA+DHA formulation (2 g/day, EPA:DHA 1.2:1) for 12 weeks as an add-on to their usual therapy.
• Those on omega-3 showed statistically significant reductions in inflammatory biomarkers, better blood-pressure control and decreased arterial stiffness, with investigators citing about a 10% drop in stiffness after 12 weeks.
• Blood pressure was assessed in clinic and with 24-hour ambulatory monitoring, and investigators reported the regimen was well tolerated without significant adverse events.
• The team said the protocol had ANMAT and ethics approval and that findings were presented at major cardiology meetings, while emphasizing the pharmaceutical-grade product differs from common over-the-counter supplements.